
26 May 2022
Goodbody Health Inc.
("Goodbody Health", or the "Company")
Goodbody Health announces the launch of its Health "MOT" diagnostic test
Goodbody Health (AQSE: GDBY) is pleased to announce that it has launched its core
Goodbody products and services are focussed on prevention and will help alleviate the pressures on the NHS in line with the NHS long term plan. We are launching to coincide with Type 2 Diabetes prevention week, highlighting 1 in 15 people in the
This health check, alongside our other diagnostic tests, will start as a trial in a number of chosen pharmacies and our own stores based in
Geremy Thomas, Executive Chairman, said: "We are very excited about the launch of the MOT product. The recent pandemic has made us all realise that our health is our most important asset, there has never been a better time to take control of your current health. With a number of clinics already on board and the testing available using new, innovative technology, our developing network will soon be able to offer the MOT as an additional product within their pharmacy".
For further information:
Marc Howells Chief Executive Officer Goodbody Health Inc. +44 (0) 20 7971 1255 enquiries@goodbodyhealth.com |
Anne Tew Chief Financial Officer Goodbody Health Inc. +44 (0) 20 7971 1255 enquiries@goodbodyhealth.com
|
|
AQSE Corporate Adviser Arden Partners plc Antonio Bossi / George Morgan + 44 (0) 20 7614 5900 |
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.